Intravitreal injection of anti-vascular endothelial growth factor (VEGF), including ranibizumab and aflibercept, has been shown to deliver an optimal visual outcome in patients with n-AMD, including PCV [7]. The gene discussed is VEGFA; the disease is age-related macular degeneration.